MedTrace Logo

Value of Analysing Under-utilised Leftover Tissue (VauLT)

NCT03832062 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-05-18

No results posted yet for this study

Summary

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.

Conditions

Interventions

OTHER

Leftover surgical tissue homogenization

Leftover surgical tissue homogenization

Sponsors & Collaborators

  • Ventana Medical Systems

    collaborator UNKNOWN

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Samra Turajlic · Royal Marsden NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2028-08-31
Completion
2028-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03832062 on ClinicalTrials.gov